Yarrow Bioscience(YARW)
$14.21+0.28 (+2.01%)
YARW
Yarrow Bioscience financials statements
$14.21
At close:+0.28 (+2.01%)
Want to see YARW full AI Analyst Report?
Yarrow Bioscience (YARW) Ratios
1,907 Followers
Yarrow Bioscience Ratios
YARW's free cash flow for Q3 2026 was $-89.96M. For the 2026 fiscal year, YARW's free cash flow was increased by $0.00 and operating cash flow was $-89.96M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.53 | 4.35 | 12.73 | 4.10 | 3.43 |
| Quick Ratio | 12.53 | 4.35 | 12.73 | 4.10 | 3.04 |
| Cash Ratio | 10.03 | 1.34 | 4.06 | 3.31 | 2.29 |
| Solvency Ratio | -11.05 | -2.69 | -3.18 | -2.42 | -3.98 |
| Operating Cash Flow Ratio | -13.83 | -2.29 | -3.36 | -3.12 | -3.06 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 27.61M | $ 49.62M | $ 87.01M | $ 28.72M | $ 44.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.28 | 1.10 | 1.31 | 1.38 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -7.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -6.94 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.02 | 0.00 | 2.08 |
| Net Debt to EBITDA | 0.90 | 0.50 | 1.04 | 0.90 | 1.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.96% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -4689.82% | -7944.71% | -6900.47% | -7189.73% | -4179.48% |
| EBITDA Margin | -4685.79% | -7943.91% | -6900.47% | -7174.63% | -4167.78% |
| Operating Profit Margin | -5219.12% | -8709.98% | -6900.47% | -7189.73% | -4179.48% |
| Pretax Profit Margin | -4689.82% | -7944.71% | -6573.58% | -7113.63% | -4700.32% |
| Net Profit Margin | -4646.14% | -7950.90% | -6710.38% | -4865.83% | -7876.37% |
| Continuous Operations Profit Margin | -4690.53% | -7945.51% | -6573.58% | -7116.35% | -4748.44% |
| Net Income Per EBT | 99.07% | 100.08% | 102.08% | 68.40% | 167.57% |
| EBT Per EBIT | 89.86% | 91.21% | 95.26% | 98.94% | 112.46% |
| Return on Assets (ROA) | -87.81% | -59.54% | -29.13% | -56.95% | -109.37% |
| Return on Equity (ROE) | -95.38% | -76.48% | -32.06% | -74.39% | -150.77% |
| Return on Capital Employed (ROCE) | -107.15% | -83.78% | -32.46% | -109.17% | -80.00% |
| Return on Invested Capital (ROIC) | -107.15% | -83.62% | -32.41% | -109.17% | -79.43% |
| Return on Tangible Assets | -87.81% | -59.54% | -29.13% | -56.95% | -109.37% |
| Earnings Yield | -106.73% | -27.92% | -118.87% | -269.82% | -139.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.10 | 0.12 |
| Payables Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 6.33 | 2.43 | 2.05 | 0.00 | 2.63 |
| Asset Turnover | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Conversion Cycle | -16520.22 | 0.00 | 0.00 | 3826.00 | 2972.93 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 3826.00 | 2972.93 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 16520.22 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 3826.00 | 2972.93 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -38.73 | -0.80 | -2.47 | -9.17 | -19.72 |
| Free Cash Flow Per Share | -38.73 | -0.80 | -2.47 | -9.17 | -19.72 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -290.36 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -290.36 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -343.15 | -118.42 | 0.00 | -161.51 |
| Operating Cash Flow to Sales Ratio | -58.11 | -67.81 | -59.77 | -61.22 | -60.54 |
| Free Cash Flow Yield | -133.49% | -23.89% | -105.87% | -339.45% | -107.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.94 | -3.56 | -0.84 | -0.37 | -0.72 |
| Price-to-Sales (P/S) Ratio | 43.53 | 284.78 | 56.45 | 18.03 | 56.38 |
| Price-to-Book (P/B) Ratio | 0.89 | 2.74 | 0.27 | 0.28 | 1.08 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.75 | -4.19 | -0.94 | -0.29 | -0.93 |
| Price-to-Operating Cash Flow Ratio | -0.75 | -4.20 | -0.94 | -0.29 | -0.93 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.05 | 0.01 | 0.01 | 0.01 |
| Enterprise Value Multiple | -0.03 | -3.09 | 0.22 | 0.65 | -0.27 |
| Enterprise Value | 786.99K | 122.85M | -6.47M | -22.31M | 10.59M |
| EV to EBITDA | -0.03 | -3.09 | 0.22 | 0.65 | -0.27 |
| EV to Sales | 1.38 | 245.20 | -15.26 | -46.76 | 11.37 |
| EV to Free Cash Flow | -0.02 | -3.60 | 0.26 | 0.76 | -0.19 |
| EV to Operating Cash Flow | -0.02 | -3.62 | 0.26 | 0.76 | -0.19 |
| Tangible Book Value Per Share | 32.46 | 1.22 | 8.64 | 9.79 | 17.01 |
| Shareholders’ Equity Per Share | 32.46 | 1.22 | 8.64 | 9.79 | 17.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | -0.00 | -0.01 |
| Revenue Per Share | 0.67 | 0.01 | 0.04 | 0.15 | 0.33 |
| Net Income Per Share | -30.96 | -0.94 | -2.77 | -7.29 | -25.65 |
| Tax Burden | 0.99 | 1.00 | 1.02 | 0.68 | 1.68 |
| Interest Burden | 1.00 | 1.00 | 0.95 | 0.99 | 1.12 |
| Research & Development to Revenue | 33.75 | 61.77 | 38.46 | 38.54 | 20.99 |
| SG&A to Revenue | 19.44 | 26.33 | 31.54 | 34.35 | 0.00 |
| Stock-Based Compensation to Revenue | 4.05 | 6.59 | 7.79 | 9.01 | 8.68 |
| Income Quality | 1.24 | 0.85 | 0.89 | 1.26 | 0.77 |
Currency in USD

